CA
NZ
UK
AU
IND
US
LB Pharmaceuticals Inc filed a Form 8-K with the SEC on September 15, 2026, disclosing the appointment of Susan G. Kozauer, M.D. as Chief Medical Officer, effective September 14, 2026.
RB Global, Inc. filed a Form 8-K with the SEC on September 15, 2026, disclosing that its board of directors authorized a $500 million increase to its existing share repurchase program and obtained Toronto Stock Exchange approval to raise the maximum number of common …
Otis Worldwide Corporation filed a Form 8-K with the SEC on September 15, 2026, disclosing that Chair, Chief Executive Officer, and President Judith F. Marks has agreed with the Board of Directors to retire no later than July 31, 2027, with a successor search …
AGNT, Inc. filed a Form 8-K on September 15, 2026, disclosing the completion on September 14, 2026, of a previously announced repurchase of 8,693,290 shares of its common stock from a trust for an aggregate purchase price of $31,991,307.20.
Evommune, Inc. filed a current report on September 15, 2026, disclosing that the Delaware-incorporated biopharmaceutical company published an updated corporate presentation on its investor relations website under Regulation FD.
USA TODAY Co., Inc. filed a Current Report on Form 8-K on September 15, 2026, disclosing the expansion of its Board of Directors from eight to nine members and the appointment of Timothy Allen as a new director, effective that same date.
BioMarin Pharmaceutical Inc. filed a Form 8-K with the SEC on September 15, 2026, disclosing its decision to discontinue development of VOXZOGO for children with Noonan syndrome.
Scholar Rock Holding Corporation filed a Form 8-K on September 15, 2026, under Regulation FD to correct an erroneous statement made by management during an investor call regarding FDA post-marketing safety commitments for ISEMBYLD (apitegromab-mstn).
The Scotts Miracle-Gro Company filed a Form 8-K with the SEC on September 15, 2026, disclosing the full redemption of its $250.0 million aggregate principal amount of 5.250% Senior Notes due 2026, which took effect on September 11, 2026.
Summit Therapeutics Inc. filed a Form 8-K on September 15, 2026, announcing that updated overall survival results from its global Phase III HARMONi clinical trial were presented at the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer.
Please wait processing your request...